Author Topic: (Abst.) Smokers w/MS have lower quality of life, more disability than non-smokers  (Read 110 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, January 7, 2017:

Quote
Mult Scler. 2017 Jan 1

Smokers with MS have greater decrements in quality of life and disability than non-smokers

Briggs FB1, Gunzler DD2, Ontaneda D3, Marrie RA4.

Author information

1Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
2Center for Health Care Research and Policy, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.
3Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
4Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

BACKGROUND:

Tobacco smoke plays a pathogenic role in multiple sclerosis (MS) and may accelerate disease progression, yet, some people with MS continue to smoke after disease onset. The average smoker reports diminished health-related quality of life (HRQOL) across many populations.

OBJECTIVES:

To describe the relationships between smoking status and HRQOL, disease activity, and global disability in a US population with MS.

METHODS:

We compared smokers to non-smokers in 950 responders to the Spring 2014 update survey completed by North American Research Committee on Multiple Sclerosis (NARCOMS) registry participants. HRQOL was assessed using Short Form-12 version 2 (SF-12v2), disease activity was investigated using eight Performance Scales (PS) and three Functionality Scales (FS). Global disability was evaluated using Patient Determined Disease Steps (PDDS) and an item response theory (IRT) summed score based on the PS and FS.

RESULTS:

Smokers had lower HRQOL ( p < 0.0001), reported more disease activity ( p < 0.05) and greater deficits in all PS and FS ( p = 6 × 10-7 to 0.05), except mobility. Smokers and non-smokers did not differ by PDDS but had substantially greater IRT global disability ( p = 2 × 10-7).

CONCLUSION:

Active smoking is meaningfully associated with deficits across multiple domains in people with MS and adds to the growing literature of the need for MS-tailored smoking cessation programs.

The abstract can be seen here.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
110 Views
Last post June 22, 2016, 05:19:31 pm
by agate
0 Replies
134 Views
Last post February 18, 2018, 03:41:00 pm
by agate
0 Replies
181 Views
Last post June 16, 2018, 02:56:04 pm
by agate
0 Replies
105 Views
Last post October 26, 2018, 11:05:06 am
by agate
0 Replies
11 Views
Last post February 15, 2023, 09:25:49 pm
by agate